Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + cyclophosphamide + docetaxel + doxorubicin
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of four distinct drugs: Bevacizumab (Avastin) - a monoclonal antibody that targets vascular endothelial growth factor (VEGF); Cyclophosphamide - a chemotherapy agent; Docetaxel - a chemotherapy agent; Doxorubicin - a chemotherapy agent. Bevacizumab is an angiogenesis inhibitor that works by preventing the formation of new blood vessels in tumors. The combination likely represents an intensive chemotherapy regimen with the addition of targeted anti-angiogenic therapy for treating certain types of cancer.
02
Targets
Beyond the preview
Go deeper on bevacizumab + cyclophosphamide + docetaxel + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + cyclophosphamide + docetaxel + doxorubicin.